Bone Marrow & Stem Cell Transplant

Latest News

February 22nd 2022

Young Donors Improve DFS in Allo-HCT Patients With Myelodysplastic Syndrome

Results from a retrospective study favor younger matched unrelated donors for consideration in the donor selection for patients with myelodysplastic syndrome.

February 14th 2022

Donor Bone Marrow Derived Macrophage Engraftment Significant in CNS of Allogeneic Transplant Patients

By Conor Killmurray

January 14th 2022

Shammo Debates the Triggers for Treatment of Patients With High-Risk Myelofibrosis

By Targeted Oncology Staff

January 7th 2022

Part 1: Benefit Shown With Transplant and Combination Therapy in Multiple Myeloma

By Targeted Oncology Staff

December 21st 2021

Cooper Analyzes the Different Data in Transplant-Eligible Multiple Myeloma

By Targeted Oncology Staff

Latest Videos

$Pano/GemBuMel is Safe and Effective in High-Risk or Relapsed/Refractory Myeloma$

Pano/GemBuMel is Safe and Effective in High-Risk or Relapsed/Refractory Myeloma

Recommendations for Treating Patients With TP53-Mutated AML or MDS

The Use of Transplant in the Post CAR T Setting

Allogeneic SCT Shows Efficacy in TP53+ AML and MDS

Role of Transplant Across Hematologic Malignancies

Mitigating Transplant-Induced GVHD

Omidubicel Increases Availability of Allogeneic Stem Cell Transplant

Long-Term Follow Up Shows Potential of Omidubicel in Hematologic Malignancies

Exploring Transplants Prior to CAR T-Cell Therapy in Hematologic Malignancies

The Role of Age in Bone Marrow and Stem Cell Transplants for MDS

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Seth A. Wander, MD, PhD; Girish Kunapareddy, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Iowa

Virginia Kaklamani, MD, DSc; Jack W. Erter III, MD, MMHC

Virtual Event

Arkansas Association of Cancer Professionals

2 Sessions are Available!

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

Seth A. Wander, MD, PhD; Kit Lu, MD

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Register now!

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Minnesota

Neil M. Iyengar, MD; Kimberly Ku, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Texas

Sheila Donnelly, MD; Virginia Kaklamani, MD, DSc

Virtual Event

Updates from Berlin: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

May 27, 2026

Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

In-Person + Virtual Event

Go to PER in Chicago

May 29-31, 2026

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Seth A. Wander, MD, PhD; Kamel Abou Hussein, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Alison K. Conlin, MD; Neil M. Iyengar, MD

Virtual Event

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

June 8, 2026

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Yan Ji, MD; Neil M. Iyengar, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH

Virtual Event

Iowa Oncology Society

1 Session is Available!

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Virtual Event

Kansas Society of Clinical Oncology

1 Session is Available!

Virtual Event

Louisiana Oncology Society

1 Session is Available!

Virtual Event

Missouri Oncology Society

1 Session is Available!

Virtual Event

New Mexico Society of Clinical Oncology

1 Session is Available!

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

In-Person + Virtual Event

25th Annual International Congress on the Future of Breast Cancer® East

July 10-11, 2026

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Video

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

More News

Roundtable Discussion: Usmani and Participants Review Using Transplant and Combination Therapy in a Patient With Newly Diagnosed Multiple Myeloma

ByTargeted Oncology Staff

December 1st 2021

A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 2 and was diagnoses with stage II standard-risk multiple myeloma.

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

ByJamie Cesanek

October 3rd 2021

Promising survival results were shown in the FORTE trial of carfilzomib plus lenalidomide, and dexamethasone induction/consolidation with autologous stem cell transplant and maintenance with carfilzomib-lenalidomide in patients with multiple myeloma.

Home Care Delivery for Patients Undergoing HSCT During COVID-19

ByNelson J. Chao, MD

September 8th 2021

Nelson J. Chao, MD, discusses a shift at Duke Cancer Institute from in-office care to home care in patients undergoing hematopoietic stem cell transplantation for hematologic malignancies.

Prolonged Reponses Following ASCT and Standard Consolidation/Induction With Daratumumab Maintenance

ByAudrey Sternberg

June 20th 2021

Benefit was seen with daratumumab maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone.

AB-205 Shows Promise in Patients With Systemic Lymphoma Undergoing HDT-ASCT

ByGina Mauro

May 21st 2021

AB-205 demonstrated robust effects and an encouraging safety profile in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.